Jayanthi Wolf

Jayanthi has had an extensive career in research and development at Merck over a 19-year period. She has broad experience in regulatory affairs, including clinical, nonclinical and manufacturing and has managed programs from preclinical development through regulatory approval.

Prior to joining Atea, during her tenure at Merck, Jayanthi served in a series of roles ranging from scientific to safety assessment and regulatory, with increasing responsibility in global regulatory affairs and clinical safety. She served as the global regulatory team leader for several products, including ERVEBO®, the first Ebola vaccine approved by the U.S. Food and Drug Administration, the European Medicines Agency and prequalified by the World Health Organization. Jayanthi earned a PhD and master’s degree in Molecular Biology and Immunology from Princeton University and a BS in Biochemistry from Susquehanna University.